Non-Alcoholic Fatty Liver Disease (NAFLD) and MTHFR 1298A > C gene polymorphism

European Review for Medical and Pharmacological Sciences

Volumn 18, Issue 2, 2014, Pages 151-159

  Catalano, D ^a   Trovato, G M ^a   Ragusa, A ^b   Martines, G F ^c   Tonzuso, A ^a   Pirri, C ^a   Buccheri, M A ^b   Trovato, F M ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b Prenatal Diagnosis and Medical Genetics AOU VE and Policlinico   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

Author keywords

Fatty liver; Genetic MTHFR polymorphism; Homocysteine; Insulin resistance; Mediterranean diet; Obesity

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALBUMIN; C REACTIVE PROTEIN; CYANOCOBALAMIN; FOLIC ACID; HEMOGLOBIN; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MTHFR PROTEIN, HUMAN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; DISEASE SEVERITY; DNA POLYMORPHISM; FEMALE; FOLIC ACID BLOOD LEVEL; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HETEROZYGOSITY; HUMAN; HYPERHOMOCYSTEINEMIA; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; NUTRITIONAL ASSESSMENT; NUTRITIONAL COUNSELING; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; VITAMIN BLOOD LEVEL; GENETIC PREDISPOSITION; GENETICS; NON-ALCOHOLIC FATTY LIVER DISEASE; SINGLE NUCLEOTIDE POLYMORPHISM;

GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INSULIN RESISTANCE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84897008662     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. ANSTEE QM, DALY AK, DAY CP. Genetics of alcoholic and nonalcoholic fatty liver disease. Semin Liver Dis 2011; 31: 128-146.
2. STICKEL F, HAMPE J. Genetic determinants of alcoholic liver disease. Gut 2011; 61: 150-159.
3. FERENCI P. Polymorphism of methylenetetrahydrofolate reductase as disease modifier- A déjà-vu in Wilson disease? J Hepatol 2011; 55: 753-755.
4. SAFFROY R, PHAM P, CHIAPPINI F, GROSS-GOUPIL M, CASTERA L, AZOULAY D, BARRIER A, SAMUEL D, DEBUIRE B, LEMOINE A. The MTHFR 677C > T polymorphism is associated with an increased risk of hepatocellular carcinoma in patients with alcoholic cirrhosis. Carcinogenesis 2004; 25:1443-1448.
5. ADINOLFI LE, INGROSSO D, CESARO G, CIMMINO A, D'ANTÒ M, CAPASSO R, ZAPPIA V, RUGGIERO G. Hyperhomocysteinemia and the MTHFR C677T polymorphism promote steatosis and fibrosis in chronic hepatitis C patients. Hepatology 2005; 41: 995-1003.
6. KALHAN SC, EDMISON J, MARCZEWSKI S, DASARATHY S, GRUCA LL, BENNETT C, DUENAS C, LOPEZ R. Methionine and protein metabolism in non-alcoholic steatohepatitis: evidence for lower rate of transmethylation of methionine. Clin Sci (Lond) 2011; 121: 179-189.
7. SERIN E, GÜÇLÜ M, ATAÇ FB, VERDI H, KAYASELÇUK F, OZER B, BILEZIKÇI B, YILMAZ U. Methylenetetrahydrofolate reductase C677T mutation and nonalcoholic fatty liver disease. Dig Dis Sci 2007; 52: 1183-1186.
8. SAZCI A, ERGUL E, AYGUN C, AKPINAR G, SENTURK O, HULAGU S. Methylenetetrahydrofolate reductase gene polymorphisms in patients with nonalcoholic steatohepatitis (NASH). Cell Biochem Funct 2008; 26: 291-296.
9. VIRDIS A, IGLARZ M, NEVES MF, AMIRI F, TOUYZ RM, ROZEN R, SCHIFFRIN EL. Effect of hyperhomocystinemia and hypertension on endothelial function in methylenetetrahydrofolate reductase-deficient mice. Arterioscler Thromb Vasc Biol 2003; 23: 1352-1357.
10. ZHANG W, SUN K, CHEN J, LIAO Y, QIN Q, MA A, WANG D, ZHU Z, WANG Y, HUI R. High plasma homocysteine levels contribute to the risk of stroke recurrence and all-cause mortality in a large prospective stroke population. Clin Sci (Lond) 2009; 118: 187-194.
11. HULTDIN J, VAN GUELPEN B, WINKVIST A, HALLMANS G, WEINEHALL L, STEGMAYR B, NILSSON TK. Prospective study of first stroke in relation to plasma homocysteine and MTHFR 677C>T and 1298A>C genotypes and haplotypes-evidence for an association with hemorrhagic stroke. Clin Chem Lab Med 2011; 49: 1555-1562.
12. FIMOGNARI FL, VIOLI F. Portal vein thrombosis in liver cirrhosis. Intern Emerg Med 2008; 3: 213-218.
13. GUÉANT-RODRIGUEZ RM, GUÉANT JL, DEBARD R, THIRION S, HONG LX, BRONOWICKI JP, NAMOUR F, CHABI NW, SANNI A, ANELLO G, BOSCO P, ROMANO C, AMOUZOU E, ARRIETA HR, SÁNCHEZ BE, ROMANO A, HERBETH B, GUILLAND JC, MUTCHINICK OM. Prevalence of methylenetetrahydrofolate reductase 677T and 1298C alleles and folate status: a comparative study in Mexican, West African, and European populations. Am J Clin Nutr 2006; 83: 701-707.
14. MA J, STAMPFER MJ, GIOVANNUCCI E, ARTIGAS C, HUNTER DJ, FUCHS C, WILLETT WC, SELHUB J, HENNEKENS CH, ROZEN R. Methylene-tetrahydro-folate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res 1997; 57: 1098-1102.
15. DE JONGE R, TISSING WJ, HOOIJBERG JH, JANSEN G, KASPERS GJ, LINDEMANS J, PETERS GJ, PIETERS R. Polymorphisms in folate-related genes and risk of pediatric acute lymphoblastic leukemia. Blood 2009; 113: 2284-2289.
16. FROSST P, BLOM HJ, MILOS R, GOYETTE P, SHEPPARD CA, MATTHEWS RG, BOERS GJ, DEN HEIJER M, KLUIJTMANS LA, VAN DEN HEUVEL LP. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-113.
17. YAMADA K, CHEN Z, ROZEN R, MATTHEWS RG. Effects of common polymorphisms on the properties of recombinant human methylene-tetrahydrofolate reductase. Proc Natl Acad Sci U S A 2001; 98: 14853-14858.
18. KOEHLER KM, BAUMGARTNER RN, GARRY PJ, ALLEN RH, STABLER SP, RIMM EB. Association of folate intake and serum homocysteine in elderly persons according to vitamin supplementation and alcohol use. Am J Clin Nutr 2001; 73: 628-637.
19. ALLEN LH. Causes of vitamin B12 and folate deficiency. Food Nutr Bull 2008; 29(2 Suppl): S20-34.
20. CATALANO D, TROVATO GM, MARTINES GF, RANDAZZO M, TONZUSO A. Bright liver, body composition and insulin resistance changes with nutritional intervention: a follow-up study. Liver Int 2008; 28: 1280-1287
21. TRICHOPOULOU A, COSTACOU T, BAMIA C, TRICHOPOULOS D. Adherence to a Mediterranean diet and survival in a Greek population. N Engl J Med 2003; 348: 2599-2608.
22. DAI J, JONES DP, GOLDBERG J, ZIEGLER TR, BOSTICK RM, WILSON PW, MANATUNGA AK, SHALLENBERGER L, JONES L, VACCARINO V. Association between adherence to the Mediterranean diet and oxidative stress. Am J Clin Nutr 2008; 88: 1364-1370.
23. BRAVATA DM, SMITH-SPANGLER C, SUNDARAM V, GIENGER AL, LIN N, LEWIS R, STAVE CD, OLKIN I, SIRARD JR. Using pedometers to increase physical activity and improve health: a systematic review. JAMA 2007; 298: 2296-2304.
24. WALLACE TM, MATTHEWS DR. The assessment of insulin resistance in man. Diabet Med 2002; 19: 527-534.
25. RUTTER MK, WILSON PW, SULLIVAN LM, FOX CS, D'AGOSTINO RB SR, MEIGS JB. Use of alternative thresholds defining insulin resistance to predict incident type 2 diabetes mellitus and cardiovascular disease. Circulation 2008; 117: 1003-1009.
26. MATHIESEN UL, FRANZÉN LE, ASELIUS H, RESJÖ M, JACOBSSON L, FOBERG U, FRYDÉN A, BODEMAR G. Increased liver echogenicity at ultrasound examination reflects degree of steatosis but not of fibrosis in asymptomatic patients with mild/moderate abnormalities of liver transaminases. Dig Liver Dis 2002; 34: 516-522.
27. STICKEL F, HAMPE J. Genetic determinants of alcoholic liver disease. Gut 2012; 61: 150-159.
28. HU KQ,, CURRIE SL, SHEN H, CHEUNG RC, HO SB, BINI EJ, MCCRACKEN JD, MORGAN T, BRÄU N, SCHMIDT WN, JEFFERS L, WRIGHT TL; VA HCV-001 STUDY GROUP. Clinical implications of hepatic steatosis in patients with chronic hepatitis C: a multicenter study of U.S. veterans. Dig Dis Sci 2007; 52: 570-578.
29. GUPTA AC, CHAUDHORY AK, SUKRITI, PANDE C, SAKHUJA P, SINGH Y, BASIR SF, SARIN SK. Peroxisome proliferators-activated receptor γ2 Pro12Ala variant is associated with body mass index in non-alcoholic fatty liver disease patients. Hepatol Int 2010; 5: 575-580.
30. HARMON RC, CALDWELL SH. Propensity for non-alcoholic fatty liver disease: more evidence for ethnic susceptibility. Liver Int 2009; 29: 4-5.
31. RIQUELME A, ARRESE M, SOZA A, MORALES A, BAUDRAND R, PÉREZ-AYUSO RM, GONZÁLEZ R, ALVAREZ M, HERNÁNDEZ V, GARCÍA-ZATTERA MJ, OTAROLA F, MEDINA B, RIGOTTI A, MIQUEL JF, MARSHALL G, NERVI F. Nonalcoholic fatty liver disease and its association with obesity, insulin resistance and increased serum levels of C-reactive protein in Hispanics. Liver Int 2009; 29: 82-88.
32. FABRIS C, TONIUTTO P, FALLETI E, FONTANINI E, CUSSIGH A, BITETTO D, FORNASIERE E, FUMOLO E, AVELLINI C, MINISINI R, PIRISI M. MTHFR C677T polymorphism and risk of HCC in patients with liver cirrhosis: role of male gender and alcohol consumption. Alcohol Clin Exp Res 2009; 33: 102-107.
33. TONIUTTO P, FABRIS C, FALLETI E, CUSSIGH A, FONTANINI E, BITETTO D, FORNASIERE E, MINISINI R, DE FEO T, MARANGONI F, PIRISI M. Methylenetetrahydrofolate reductase C677T polymorphism and liver fibrosis progression in patients with recurrent hepatitis C. Liver Int 2008; 28: 257-263.
34. CHEN J, GIOVANNUCCI E, KELSEY K, RIMM EB, STAMPFER MJ, COLDITZ GA, SPIEGELMAN D, WILLETT WC, HUNTER DJ. A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal cancer. Cancer Res 1996; 56: 4862-4864.
35. LEVINE AJ, FIGUEIREDO JC, LEE W, POYNTER JN, CONTI D, DUGGAN DJ, CAMPBELL PT, NEWCOMB P, MARTINEZ ME, HOPPER JL, LE MARCHAND L, BARON JA, LIMBURG PJ, ULRICH CM, HAILE RW. Genetic variability in the MTHFR gene and colorectal cancer risk using the colorectal cancer family registry. Cancer Epidemiol Biomarkers Prev 2010; 19: 89-100.
36. LEE JE, WEI EK, FUCHS CS, HUNTER DJ, LEE IM, SELHUB J, STAMPFER MJ, WILLETT WC, MA J, GIOVANNUCCI E. Plasma folate, methylenetetrahydrofolate reductase (MTHFR), and colorectal cancer risk in three large nested case-control studies. Cancer Causes Control 2012; 23: 537-545.
37. PLATEK ME, SHIELDS PG, MARIAN C, MCCANN SE, BONNER MR, NIE J, AMBROSONE CB, MILLEN AE, OCHS-BALCOM HM, QUICK SK, TREVISAN M, RUSSELL M, NOCHAJSKI TH, EDGE SB, FREUDENHEIM JL. Alcohol consumption and genetic variation in methylenetetrahydrofolate reductase and 5-methyltetrahydrofolatehomocysteine methyltransferase in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev 2009; 18: 2453-2459.
38. DEDOUSSIS GV, PANAGIOTAKOS DB, CHRYSOHOOU C, PITSAVOS C, ZAMPELAS A, CHOUMERIANOU D, STEFANADIS C. Effect of interaction between adherence to a Mediterranean diet and the methylenetetrahydrofolate reductase 677C->T mutation on homocysteine concentrations in healthy adults: the ATTICA Study. Am J Clin Nutr 2004; 80: 849-854.
39. WINKELMAYER WC, SUNDER-PLASSMANN G, HUBER A, FÖDINGER M. Patterns of co-occurrence of three single nucleotide polymorphisms of the 5,10-methylenetetrahydrofolate reductase gene in kidney transplant recipients. Eur J Clin Invest 2004; 34: 613-618.
40. COLEMAN DL. Obesity genes: beneficial effects in heterozygous mice. Science 1979; 203: 663-665.
41. LIVADAS S, DRACOPOULOU M, LAZAROPOULOU C, PAPASSOTIRIOU I, SERTEDAKI A, ANGELOPOULOS GN, CHROUSOS GP, DACOU-VOUTETAKIS C. A favorable metabolic and antiatherogenic profile in carriers of CYP21A2 gene mutations supports the theory of a survival advantage in this population. Horm Res 2009; 72: 337-343.
42. DORNER TE, RIEDER A. Obesity paradox in elderly patients with cardiovascular diseases. Int J Cardiol 2012; 155: 56-65.
43. BLOM HJ. Mutated 5,10-methylenetetrahydrofolate reductase, hyperhomocysteinemia and risk for cardiovascular disease. Nature, nurture or nonsense? Eur J Clin Invest 2011; 31: 6-8.
44. REISS G, KEEFFE EB. Role of liver biopsy in the management of chronic liver disease: selective rather than routine. Rev Gastroenterol Disord 2005; 5: 195-205.
45. NEGRO F. Steatosis in chronic hepatitis C: friend or foe? Liver Int 2008: 28: 294-296.
46. YU AS, KEEFFE EB. Elevated AST or ALT to nonalcoholic fatty liver disease: accurate predictor of disease prevalence? Am J Gastroenterol 2003; 98: 955-956.
47. NEGRO F. Steatosis and insulin resistance in response to treatment of chronic hepatitis C. J Viral Hepat 2012; 19(Suppl 1): 42-47.
48. YU AS, KEEFFE EB. Nonalcoholic fatty liver disease. Rev Gastroenterol Disord 2002; 2: 11-19.
49. CATALANO D, TROVATO GM, MARTINES GF, PIRRI C, TROVATO FM. Renal function and severity of bright liver. Relationship with insulin resistance, intrarenal resistive index, and glomerular filtration rate. Hepatol Int 2011; 5: 822-829.